# Evaluation of EFficacy and SaFEty of Leukotac (Inolimomab) in Pediatric Patients With SR-aGvHD

> **NCT04289103** · PHASE3 · UNKNOWN · sponsor: **ElsaLys Biotech** · enrollment: 65 (estimated)

## Conditions studied

- Steroid Refractory GVHD

## Interventions

- **BIOLOGICAL:** Inolimomab (Leukotac)

## Key facts

- **NCT ID:** NCT04289103
- **Lead sponsor:** ElsaLys Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-10
- **Primary completion:** 2022-12
- **Final completion:** 2024-06
- **Target enrollment:** 65 (ESTIMATED)
- **Last updated:** 2020-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04289103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04289103, "Evaluation of EFficacy and SaFEty of Leukotac (Inolimomab) in Pediatric Patients With SR-aGvHD". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04289103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*